Related Experiment Videos
[Control of cisplatin-induced delayed emesis]
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed
|December 1, 1991
Summary
This study shows a new antiemetic regimen effectively prevents delayed nausea and vomiting in patients receiving cisplatin chemotherapy. The treatment significantly reduced symptoms compared to no antiemetic use on subsequent days.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Context:
- Cisplatin chemotherapy is associated with significant acute and delayed nausea and vomiting.
- Managing delayed emesis remains a challenge despite effective acute antiemetic control.
- Patient-reported outcomes in chemotherapy are crucial for treatment adherence and quality of life.
Purpose:
- To evaluate the efficacy of a specific antiemetic regimen for preventing delayed nausea and vomiting after cisplatin chemotherapy.
- To compare the incidence of delayed emesis and nausea in patients receiving a multi-day antiemetic protocol versus standard care.
Summary:
- A regimen including metoclopramide, dexamethasone, and lorazepam was administered to patients undergoing cisplatin chemotherapy.
- Patients received high-dose antiemetics on the day of chemotherapy, followed by a specific intravenous and oral regimen on days 2-5.
- Delayed vomiting and nausea incidence were significantly lower (27.9% and 39.4%, respectively) compared to patients not receiving post-chemotherapy antiemetics (69.8% and 79.4%).
Impact:
- The evaluated antiemetic regimen demonstrates high effectiveness in preventing delayed chemotherapy-induced nausea and vomiting.
- The side effect profile of the regimen was mild and acceptable, suggesting good tolerability.
- This therapeutic approach offers a promising strategy to improve patient comfort and adherence during cisplatin-based chemotherapy.